Oral TREM2 agonist VG-3927 reaches the clinic with preclinical and first-in-human data
- The paper reports preclinical and first-in-human evaluation of VG-3927 (SAR448851), an orally dosed small-molecule TREM2 agonist for Alzheimer's disease.
- Public reports describe good tolerability across ascending doses, central nervous system penetration, and a drop in the soluble TREM2 marker in cerebrospinal fluid.
- This summary rests on the article listing and secondary reports, not the full text.
💡 Points
Most TREM2 efforts are antibodies, so a brain-penetrant oral agonist that shifts a CSF pharmacodynamic marker is a notable modality shift. The open question is whether lower soluble TREM2 reflects real receptor activation, since a marker can move without microglial function changing. The first-in-human data show exposure and engagement, not efficacy.